Why steroid injections leave a structural gap

For many patients, the pattern is recognisable: a corticosteroid injection brings meaningful relief for weeks or months, then the same pain returns. That cycle has a structural explanation.

Corticosteroid works by suppressing the local inflammatory response — calming swelling, reducing pain signals, and settling an acute flare. In joints where inflammation is the dominant driver, this is clinically valuable. The difficulty arises when the underlying cause is not inflammation alone but confirmed focal cartilage loss: tissue that is physically absent from the joint surface.

Cartilage is avascular — it has no meaningful blood supply of its own. The body's standard injury response, which delivers repair cells and growth factors through the bloodstream, cannot reach the joint surface in sufficient quantities. Once a full-thickness focal defect forms, no amount of inflammation suppression can restore the missing structural material. In that scenario, steroid is not failing in any technical sense; it was simply not designed to address a structural deficit.

How common are these presentations? Two large arthroscopy studies — Widuchowski et al (25,124 procedures) and Curl et al (31,516 procedures) — found focal cartilage defects to be routine findings, frequently identified alongside meniscal pathology. The clinical question is therefore not whether such defects are unusual, but whether the treatment chosen is matched to the nature of the problem.

What corticosteroid does well — and where it stops

A 2017 randomised controlled trial published in JAMA (McAlindon et al) offers a useful clinical anchor: patients receiving repeated intra-articular triamcinolone over two years showed significantly greater cartilage volume loss than those receiving saline. That finding has shaped how clinicians approach long-term steroid use — not as a reason to avoid it, but as a reason to understand its proper scope.

Within that scope, corticosteroid has clear and legitimate roles. For an acute inflammatory flare — a joint that has become hot, swollen, and acutely painful — it can settle symptoms quickly and restore function while a longer-term plan is considered. As a diagnostic tool, a strong positive response helps confirm that pain is originating from inside the joint rather than from surrounding soft tissue, which directly informs what comes next. Used judiciously before another procedure, it can also reduce local inflammation and make a subsequent intervention more straightforward.

The limit arrives when ongoing injections are being used to manage a confirmed focal structural defect rather than an inflammatory episode. At that point, the returns diminish — not because the injection is being used incorrectly, but because the tool was not designed for a structural problem. That distinction is the clinical pivot: once imaging confirms tissue loss rather than inflammation alone, a different category of treatment becomes the relevant consideration.

How ChondroFiller works at the structural level

Placed directly into the cartilage defect under ultrasound guidance — in an outpatient appointment, not a surgical or theatre setting — ChondroFiller Liquid is a biodegradable Type I collagen scaffold (CE-marked as a Class III medical device). Within three to five minutes of injection, the liquid conforms to the defect contour and sets into a stable three-dimensional hydrogel, filling the structural void that surrounding tissue cannot self-repair.

The scaffold acts as a temporary framework. It draws the patient's own progenitor cells — migrating from the synovium and subchondral bone — into the defect, where they differentiate into chondrocyte-like cells and begin laying down new cartilage matrix. The scaffold itself biodegrades progressively as the body's repair tissue takes its place. This mechanism is called acellular matrix-induced chondrogenesis: acellular because the product contains no donor or harvested cells, and chondrogenesis because the recruited cells are directed towards a cartilage-forming pathway. No prior biopsy or cell extraction is required, so the entire procedure is completed in a single image-guided outpatient appointment.

The distinction from earlier stages of many patients' journeys is structural. Corticosteroid modifies the biological environment around the defect; hyaluronic acid lubricates the joint surface. Neither addresses the defect itself. ChondroFiller supports the body's own repair processes at the site of actual tissue loss — providing the scaffold that avascular cartilage cannot generate independently.

Which patients are suitable candidates

Not every patient with joint pain and a history of steroid injections is a candidate for ChondroFiller — and being clear about that is clinically important.

The treatment is designed for focal articular cartilage defects up to approximately 12 cm² in adults aged 18 or over. Crucially, the surrounding cartilage needs to be structurally sound enough to hold the repair: ChondroFiller fills a defined area of tissue loss; it does not address generalised joint degeneration. Patients with severe, widespread osteoarthritis affecting the joint as a whole fall outside the indication — their primary problem is diffuse joint failure rather than a contained structural defect.

The clinical gate is MRI confirmation. Once imaging identifies focal full-thickness cartilage loss, the question becomes whether that structural defect — rather than generalised inflammation — is the patient's primary driver of symptoms. If it is, corticosteroid cannot address it by design: a structural void does not resolve with anti-inflammatory treatment, regardless of dose or frequency. The logical step at that point is a treatment that targets the defect itself.

ChondroFiller has been applied across the knee, hip, wrist, ankle, and smaller joints, which makes it a viable option for active patients and those with occupational or sporting demands on multiple joint surfaces. For patients attending MSK Doctors in Sleaford, diagnostic MRI is available on-site through the clinic's Open MRI scanner — that assessment can begin without waiting-list delays, as part of the same diagnostic pathway that determines candidacy.

Self-referral is accepted; a consultation and imaging review remain the necessary first step before any treatment decision is made.

What the evidence shows for outcomes

The most detailed prospective data published to date comes from a 2025 study by Demmer et al (PMC12498443), which followed 59 patients with intra-articular distal radius fractures, 25 of whom had residual chondral defects filled with ChondroFiller. At follow-up arthroscopy, those treated with ChondroFiller showed significantly better cartilage quality: median Outerbridge scores of 1.5 versus 3.0 in controls (P=0.006), and ICRS grades of 1 versus 3 (P=0.002). Those are not marginal differences — they represent a clinically meaningful step up in cartilage surface quality between the two groups.

Knee data from an April 2025 expert clinical evaluation report shows consistent IKDC score improvements of approximately 30 points at 12 months — a change that exceeds the threshold for clinical significance in patient-reported knee function. Across published cohorts spanning the knee, hip, and small joints, 70–85% of patients report clinically meaningful reductions in pain and improvements in mobility.

What the limitations mean in practice

Two findings deserve direct attention rather than a footnote. A 2024 in-vitro biomechanical study by Pieringer et al (PMC11564272) found that ChondroFiller could not reduce damage to opposing cartilage from Grade IV focal lesions under cyclic loading — the likely reason being early scaffold instability before the hydrogel has fully integrated. The clinical implication is straightforward: patients are advised to delay full weight-bearing after the injection. This is a designed-in part of the post-procedure protocol, not an unexpected complication, and it is why candidate selection and aftercare planning matter.

The Demmer study also identified that overfilling the defect leads to fibrous tissue formation, whereas flush application avoids it entirely. Precise image-guided placement — filling the defect level with the surrounding surface — is therefore not merely good practice; it directly affects the quality of the resulting repair tissue.

Large-scale randomised controlled trials are still underway, which is worth acknowledging — but the existing cohort data is specific, peer-reviewed, and consistent enough to inform a meaningful clinical conversation. These limitations are precisely why ChondroFiller is offered through a consultant-led assessment rather than as a walk-in procedure.

Access, cost, and booking without a referral

ChondroFiller is not available on the NHS. For patients who have exhausted steroid injections and want to address the structural defect rather than manage its symptoms, that creates a real access gap: the treatment is self-funded private care, with guide costs starting from approximately £3,000 — confirm current pricing directly with the clinic at the time of consultation.

For patients in Lincolnshire and the wider non-London catchment, MSK Doctors offers consultant-led assessment and ultrasound-guided ChondroFiller injection at clinics in Sleaford (NG34), which houses an Open MRI scanner, and Grantham (NG31). No GP referral is needed, and there are no NHS-style waiting lists. London-based patients can access the same pathway through the London Cartilage Clinic.

None of this is the right path for every patient. When the problem is generalised inflammation rather than a confirmed focal defect, or when a patient is outside the 18+ focal-defect indication, the honest answer may be that ChondroFiller does not apply. The appropriate starting point — for anyone weighing this decision — is a consultant assessment and MRI review: not to begin treatment, but to find out whether the structural conditions for it actually exist. To arrange that assessment without a referral, visit mskdoctors.com.